Theriva Biologics, Inc. (TOVX)
(Delayed Data from AMEX)
$0.33 USD
0.00 (1.13%)
Updated Oct 28, 2025 04:00 PM ET
After-Market: $0.32 -0.01 (-3.41%) 7:58 PM ET
NA Value NA Growth NA Momentum NA VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TOVX 0.33 0.00(1.13%)
Will TOVX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TOVX based on the 1-3 month trading system that more than doubles the S&P 500.

Other News for TOVX
Narrow Range Bar appears for TOVX after 5.04% move
Empery Asset Management, LP Reduces Stake in Theriva Biologics Inc
Is TOVX primed for upward momentum? Pocket Pivot shows up after gaining 0.88%
12 Health Care Stocks Moving In Friday's Intraday Session
Bullish Engulfing appears for TOVX after 17.12% move